{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:34:48Z","timestamp":1790472888159,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The emergence of drug resistant viruses, together with the possibility of increased virulence, is an important concern in the development of new antiviral compounds. Cidofovir (CDV) is a phosphonate nucleotide that is approved for use against cytomegalovirus retinitis and for the emergency treatment of smallpox or complications following vaccination. One mode of action for CDV has been demonstrated to be the inhibition of the viral DNA polymerase.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We have isolated several CDV resistant (CDV<jats:sup>R<\/jats:sup>) vaccinia viruses through a one step process, two of which have unique single mutations within the DNA polymerase. An additional resistant virus isolate provides evidence of a second site mutation within the genome involved in CDV resistance. The CDV<jats:sup>R<\/jats:sup> viruses were 3\u20137 fold more resistant to the drug than the parental viruses. The virulence of the CDV<jats:sup>R<\/jats:sup> viruses was tested in mice inoculated intranasally and all were found to be attenuated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Resistance to CDV in vaccinia virus can be conferred individually by at least two different mutations within the DNA polymerase gene. Additional genes may be involved. This one step approach for isolating resistant viruses without serial passage and in the presence of low doses of drug minimizes unintended secondary mutations and is applicable to other potential antiviral agents.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1743-422x-5-58","type":"journal-article","created":{"date-parts":[[2008,5,14]],"date-time":"2008-05-14T18:13:49Z","timestamp":1210788829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Isolation and characterization of cidofovir resistant vaccinia viruses"],"prefix":"10.1186","volume":"5","author":[{"given":"Marie N","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Obraztsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earl R","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra C","family":"Quenelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy A","family":"Keith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N","family":"Prichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W","family":"Moyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,5,14]]},"reference":[{"key":"407_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2217\/17460913.2.1.17","volume":"2","author":"S Parker","year":"2007","unstructured":"Parker S, Nuara A, Buller RM, Schultz DA: Human monkeypox: an emerging zoonotic disease. Future Microbiol 2007, 2: 17-34. 10.2217\/17460913.2.1.17","journal-title":"Future Microbiol"},{"key":"407_CR2","doi-asserted-by":"publisher","first-page":"11084","DOI":"10.1128\/JVI.00423-07","volume":"81","author":"MM Adams","year":"2007","unstructured":"Adams MM, Rice AD, Moyer RW: Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J Virol 2007, 81: 11084-11095. 10.1128\/JVI.00423-07","journal-title":"J Virol"},{"key":"407_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.virol.2003.11.015","volume":"318","author":"RM Buller","year":"2004","unstructured":"Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY: Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004, 318: 474-481. 10.1016\/j.virol.2003.11.015","journal-title":"Virology"},{"key":"407_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1128\/AAC.48.2.404-412.2004","volume":"48","author":"DC Quenelle","year":"2004","unstructured":"Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Kern ER: Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004, 48: 404-412. 10.1128\/AAC.48.2.404-412.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"407_CR5","doi-asserted-by":"publisher","first-page":"9391","DOI":"10.1128\/JVI.00605-06","volume":"80","author":"G Andrei","year":"2006","unstructured":"Andrei G, Gammon DB, Fiten P, De CE, Opdenakker G, Snoeck R, Evans DH: Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J Virol 2006, 80: 9391-9401. 10.1128\/JVI.00605-06","journal-title":"J Virol"},{"key":"407_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1128\/AAC.46.5.1329-1335.2002","volume":"46","author":"DF Smee","year":"2002","unstructured":"Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW: Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother 2002, 46: 1329-1335. 10.1128\/AAC.46.5.1329-1335.2002","journal-title":"Antimicrob Agents Chemother"},{"key":"407_CR7","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1128\/AAC.00380-06","volume":"50","author":"RS Kornbluth","year":"2006","unstructured":"Kornbluth RS, Smee DF, Sidwell RW, Snarsky V, Evans DH, Hostetler KY: Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob Agents Chemother 2006, 50: 4038-4043. 10.1128\/AAC.00380-06","journal-title":"Antimicrob Agents Chemother"},{"key":"407_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/095632020501600306","volume":"16","author":"DF Smee","year":"2005","unstructured":"Smee DF, Wandersee MK, Bailey KW, Hostetler KY, Holy A, Sidwell RW: Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice. Antivir Chem Chemother 2005, 16: 203-211.","journal-title":"Antivir Chem Chemother"},{"key":"407_CR9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1128\/AAC.46.4.991-995.2002","volume":"46","author":"ER Kern","year":"2002","unstructured":"Kern ER, Hartline C, Harden E, Keith K, Rodriguez N, Beadle JR, Hostetler KY: Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002, 46: 991-995. 10.1128\/AAC.46.4.991-995.2002","journal-title":"Antimicrob Agents Chemother"},{"key":"407_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/317813a0","volume":"317","author":"RM Buller","year":"1985","unstructured":"Buller RM, Smith GL, Cremer K, Notkins AL, Moss B: Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985, 317: 813-815. 10.1038\/317813a0","journal-title":"Nature"},{"key":"407_CR11","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1128\/AAC.01447-06","volume":"51","author":"MN Prichard","year":"2007","unstructured":"Prichard MN, Keith KA, Johnson MP, Harden EA, McBrayer A, Luo M, Qiu S, Chattopadhyay D, Fan X, Torrence PF, Kern ER: Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrob Agents Chemother 2007, 51: 1795-1803. 10.1128\/AAC.01447-06","journal-title":"Antimicrob Agents Chemother"},{"key":"407_CR12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/0042-6822(81)90150-1","volume":"113","author":"RC Condit","year":"1981","unstructured":"Condit RC, Motyczka A: Isolation and preliminary characterization of temperature-sensitive mutants of vaccinia virus. Virology 1981, 113: 224-241. 10.1016\/0042-6822(81)90150-1","journal-title":"Virology"},{"key":"407_CR13","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1128\/AAC.44.6.1506-1511.2000","volume":"44","author":"RJ Rybak","year":"2000","unstructured":"Rybak RJ, Hartline CB, Qiu YL, Zemlicka J, Harden E, Marshall G, Sommadossi JP, Kern ER: In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections. Antimicrob Agents Chemother 2000, 44: 1506-1511. 10.1128\/AAC.44.6.1506-1511.2000","journal-title":"Antimicrob Agents Chemother"},{"key":"407_CR14","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2144\/97236st07","volume":"23","author":"S Chakrabarti","year":"1997","unstructured":"Chakrabarti S, Sisler JR, Moss B: Compact, synthetic, vaccinia virus early\/late promoter for protein expression. Biotechniques 1997, 23: 1094-1097.","journal-title":"Biotechniques"},{"key":"407_CR15","doi-asserted-by":"publisher","first-page":"9168","DOI":"10.1128\/JVI.79.14.9168-9179.2005","volume":"79","author":"BG Luttge","year":"2005","unstructured":"Luttge BG, Moyer RW: Suppressors of a host range mutation in the rabbitpox virus serpin SPI-1 map to proteins essential for viral DNA replication. J Virol 2005, 79: 9168-9179. 10.1128\/JVI.79.14.9168-9179.2005","journal-title":"J Virol"},{"key":"407_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev.biophys.29.1.291","volume":"29","author":"MA Marti-Renom","year":"2000","unstructured":"Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A: Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000, 29: 291-325. 10.1146\/annurev.biophys.29.1.291","journal-title":"Annu Rev Biophys Biomol Struct"},{"key":"407_CR17","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/jvi.65.2.869-879.1991","volume":"65","author":"JA Taddie","year":"1991","unstructured":"Taddie JA, Traktman P: Genetic characterization of the vaccinia virus DNA polymerase: identification of point mutations conferring altered drug sensitivities and reduced fidelity. J Virol 1991, 65: 869-879.","journal-title":"J Virol"},{"key":"407_CR18","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1128\/jvi.67.7.4323-4336.1993","volume":"67","author":"JA Taddie","year":"1993","unstructured":"Taddie JA, Traktman P: Genetic characterization of the vaccinia virus DNA polymerase: cytosine arabinoside resistance requires a variable lesion conferring phosphonoacetate resistance in conjunction with an invariant mutation localized to the 3'-5' exonuclease domain. J Virol 1993, 67: 4323-4336.","journal-title":"J Virol"},{"key":"407_CR19","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1128\/jvi.63.9.4060-4063.1989","volume":"63","author":"FM DeFilippes","year":"1989","unstructured":"DeFilippes FM: Site of the base change in the vaccinia virus DNA polymerase gene which confers aphidicolin resistance. J Virol 1989, 63: 4060-4063.","journal-title":"J Virol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-5-58.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T01:25:12Z","timestamp":1630459512000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-5-58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,14]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["407"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-5-58","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,14]]},"assertion":[{"value":"18 April 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"58"}}